8-OH-DPAT (Sigma, St. Louis, MO) was dissolved in 0.9% saline
and administered subcutaneously in a volume of 1 ml/kg of body weight.
4-Iodo-N-[2-[4-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-benzamide hydrochloride (p-MPPI) (Research Biochemicals International,
Natick, MA) was dissolved in sterile water and sonicated for 10 to 20
min, and then brought to a pH of approximately 5.2 with 0.1 M NaOH.
p-MPPI was administered subcutaneously in a volume of 4 ml/kg of
body weight. Infusions of 8-OH-DPAT into either the median or the
dorsal raphe ́ nucleus were administered in a volume of 0.5 μl over 1
min, with the injection needle left in place for 1 min after the infusion
to minimize efflux. (+)-N-Methyl-g-[4-(trifluoromethyl)phenoxy]-benzenepropanamine hydrochloride (fluoxetine) (Research Biochemicals In-ternational) was dissolved in saline and administered intraperitoneally
in a volume of 1 ml/kg of body weight.
